Lynozyfic J Code: J9601

Drug & Product Overview

HCPCS Descriptor Injection, linvoseltamab-gcpt, 1 mg

HCPCS Added Date April 1, 2026

Manufacturer Regeneron Pharmaceuticals

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution, Concentrate

About Lynozyfic

Lynozyfic is a medication aligned to the HCPCS J Code: J9601 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Regeneron Pharmaceuticals.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Package	Manufacturer	HCPCS Units	WAC	AWP
61755-0054-01	5 MG / 2.5 ML Lynozyfic Intravenous Injection 5 MG/2.5ML - 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-054-01) / 2.5 mL in 1 VIAL, SINGLE-DOSE (61755-054-00)	Regeneron Pharmaceuticals, Inc.	5	$479.40 $95.88 / unit	$575.28 $115.056 / unit
61755-0056-01	200 MG / 10 ML Lynozyfic Intravenous Injection 200 MG/10ML - 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-056-01) / 10 mL in 1 VIAL, SINGLE-DOSE (61755-056-00)	Regeneron Pharmaceuticals, Inc.	200	$19,176.00 $95.88 / unit	$23,011.20 $115.056 / unit

Effective 10/1/26 (WAC & AWP)

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Lynozyfic Pricing & Reimbursement

Historical Graphing and Billing Calculator

NDC Package

HCPCS Units

Markup / Markdown

%

Common:

Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.

Estimated Reimbursement

Lynozyfic Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 16.79%

Avg. Days to File 7.3days

Avg. Days to Pay 28.4days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9601 claims analytics on FocalPoint →

Lynozyfic CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Lynozyfic Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

relapsed or refractory multiple myeloma

Frequently Asked Questions

Is there an available Lynozyfic billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for Lynozyfic.

Are there any available Lynozyfic patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for Lynozyfic.

Where can I find Lynozyfic prescribing information?

Lynozyfic prescribing information can be found at the link below. Visit Here →

Where can I find Lynozyfic side effect information?

Information regarding Lynozyfic's side effects can be found at MedlinePlus. Visit Here →

Does billing Lynozyfic require JZ/JW wastage modifiers?

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.